NN103 Beat MG releases two videos to raise awareness for Myasthenia Gravis

The NN103 Beat MG study Principal Investigator announces the release of two videos to raise awareness about myasthenia gravis (MG) and to provide details about the clnical trial. The first is an overview of the disease. The second, an overview of the study.

MG is a chronic autoimmune neurological disorder of neuromuscular transmission affecting approximately 75,000 individuals in the US alone. Common symptoms include a drooping eyelid, double vision, slurred speech, difficulty chewing and swallowing, weakness in the arms and legs, chronic muscle fatigue, and difficulty breathing. Despite current therapies a subset of patients continue to have symptoms or have intolerable medication side effects. The purpose of the NN103 Beat MG study is to find out the effect and safety of a new use of the drug rituximab in MG patients who are on prednisone. Please visit the NN103 Beat MG study page for further information.